Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Charting the prostate epigenomic landscape from transformation to progression

ABSTRACT: We generate transcription factor, histone modification and ATAC cistromes in nomal prostate epithelium, primary prostate tumor and metastatic prostate cancer human specimens

ORGANISM(S): Homo sapiens

PROVIDER: GSE130408 | GEO | 2020/06/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Charting the prostate epigenomic landscape from transformation to progression

Project description:We generate histone modification and ATAC cistromes in primary prostate cancer human specimens

2020-10-01 | GSE146617 | GEO

Charting the prostate epigenomic landscape from transformation to progression

Project description:Charting the prostate epigenomic landscape from transformation to progression

| PRJNA540151 | ENA

Charting the prostate epigenomic landscape from transformation to progression

Project description:Charting the prostate epigenomic landscape from transformation to progression

| PRJNA611511 | ENA

An androgen receptor switch underlies lineage infidelity to drive neuroendocrine prostate cancer

Project description:We generate transcription factor, histone modification and ATAC cistromes in castration-resistant prostate cancer (CRPC) and treatment-induced neuroendocrine prostate cancer (tNEPC) specimens.

2021-07-15 | GSE138460 | GEO

Prostate cancer progression: From non-malignant to bone metastasisProstate cancer progression: From non-malignant to bone metastasis

Project description:Proteome characterization of gland confined prostate tumors and non-malignant prostate tissue. Whole cell protein extracts were purified from FFPE radical prostatectomy specimens for a total of 28 tumor samples and 8 adjacent non-malignant prostate tissues. Associated ProteomeXchange identifiers: PXD003430, PXD003452, PXD003515, PXD004132, PXD003615, PXD003636. Quantitative proteomic analysis of adjacent non-malignant prostate tissue (n=8) and gland confined prostate tumors (n=28) obtained from radical prostatectomy procedures; and bone metastatic prostate tumors (n=22) obtained from patients operated to relief spinal cord compression. At the time of surgery, most metastatic patients had relapsed after androgen-deprivation therapy, while 5 were previously untreated.

2018-08-21 | PXD009868 | Pride

Cistrome-partitioning reveals convergence of somatic mutations and risk-variants on master transcription regulators in primary prostate tumors

Project description:Thousands of noncoding somatic Single Nucleotide Variants (SNVs) of unknown function are reported in tumors. Partitioning the genome according to cistromes, reveals the enrichment of somatic SNVs in prostate tumors as opposed to adjacent normal tissue cistromes of master transcription regulators, including AR, FOXA1 and HOXB13. This parallels enrichment of prostate cancer genetic predispositions over these transcription regulators’ tumor cistromes, exemplified at the 8q24 locus harboring both risk-variants and somatic SNVs in cis-regulatory elements, upregulating MYC expression and altering the binding of transcription regulators to DNA. However, Massively-Parallel Reporter Assays reveal that few SNVs can alter the transactivation potential of individual CREs. Instead, SNVs accumulate, similarly to inherited riskvariants, in cistromes of master transcription regulators required for prostate cancer development. Significance Difficulties in inferring the biological significance of noncoding mutations have limited their inclusion in precision genomics medicine pipelines. Most attempts to delineate a role for noncoding mutations relied on detecting evidence for positive selection within individual CREs, such as reported for the TERT gene promoter. By considering the enrichment of noncoding mutations in cistromes as opposed to individual CREs, we reveal their specificity towards master transcription regulators that promote prostate cancer development, a feature shared with inherited risk-variants. Overall, our work provides a blueprint for the functional interpretation of noncoding mutations in genomic tests relying on defining cis-regulatory units according to cistrome-partitioning to identify cancer driver transcription regulators.

2019-12-01 | GSE137527 | GEO

The proteome of localized prostate cancer, part 1

2016-06-01 | PXD003430 | Pride

The proteome of localized prostate cancer, part 5

2016-06-01 | PXD003615 | Pride

The proteome of localized prostate cancer, part 6

2016-06-01 | PXD003636 | Pride

The proteome of localized prostate cancer, part 4

2016-06-01 | PXD004132 | Pride